<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868802</url>
  </required_header>
  <id_info>
    <org_study_id>ABC KET-DRT-01-2013</org_study_id>
    <nct_id>NCT01868802</nct_id>
  </id_info>
  <brief_title>Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population</brief_title>
  <official_title>Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paul J. Lamothe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American British Cowdray Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized multicentric parallel arms study involving the use of ketamine for
      treatment-resistant depression will be held at three national health provider clinics in the
      Mexican population. The purpose of this study is to determine whether clinical response seen
      in previous studies is replicable in this population.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in baseline HDRS Score</measure>
    <time_frame>20 minutes before and 40 minutes after ketamine infusion.</time_frame>
    <description>The Hamilton Depression Rating Scale (HDRS) baseline score will be measured 20 minutes before ketamine infusion. After 40 minutes post-infusion, a second HDRS score will be obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily change in HDRS post-ketamine infusion.</measure>
    <time_frame>1,2,3,4,5,6 and 7. Days after ketamine infusion</time_frame>
    <description>On a daily basis, from day 1-7 post-ketamine infusion, changes in HDRS score will be measured during the daily psychiatric evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline blood pressure (BP).</measure>
    <time_frame>20 minutes before ketamine infusion.</time_frame>
    <description>Baseline BP will be measured during the physical examination 20 minutes before ketamine infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in blood pressure (BP)</measure>
    <time_frame>every 5 minutes in a 300 minutes period</time_frame>
    <description>BP will be monitored continuously for a 4-hour period. BP assessments will be taken every five minutes for the period mentioned. The assessment will start 20 minutes before ketamine administration and will finish 4hrs after starting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Depressive Disorder,</condition>
  <condition>Treatment-Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Ketamine treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control, placebo treated</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.</description>
    <arm_group_label>Ketamine treated</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline at 0.9% intravenous infusion will be administered over 40 minutes.</description>
    <arm_group_label>Control, placebo treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-65 years old

          -  Mayor Depressive Disorder Diagnosis based on DSM-IV TR.

          -  Classification of MDD as treatment-resistant.

          -  No brain structural abnormalities as evidenced by an MRI scan.

          -  Signed acceptance of Informed Consent.

        Exclusion Criteria:

          -  Other psychiatric diagnosis apart from MDD.

          -  Substance abuse or dependence (prior or during study).

          -  Pregnancy.

          -  Congestive heart disease.

          -  Personal history of psychosis.

          -  First-degree relative with history of psychosis.

          -  Glaucoma.

          -  Present neurological disease.

          -  High blood or pulmonary artery pressure.

          -  Declining the signing of the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J Lamothe, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>American British Cowdray Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David N Lopez-Garza, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>American British Cowdray Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Ruiz-Alvarez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>American British Cowdray Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul J Lamothe, M.D.</last_name>
    <phone>+52 (55) 11031750</phone>
    <email>paul@lamothe.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David N Lopez-Garza, M.D.</last_name>
    <phone>+ 52 (55) 11031750</phone>
    <email>davidlopezgarza@prodigy.net.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ABC Neurological Center</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>05300</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo San Esteban, M.D.</last_name>
      <phone>+52 (55) 52308000</phone>
      <email>esanesteban@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Paul J Lamothe Molina, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>March 13, 2015</last_update_submitted>
  <last_update_submitted_qc>March 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>American British Cowdray Medical Center</investigator_affiliation>
    <investigator_full_name>Paul J. Lamothe</investigator_full_name>
    <investigator_title>Chief of the Research Department, Neurological Center.</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Depression</keyword>
  <keyword>Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

